CTAD Lessons for 2020: More Phase 2 Trials, More Diversity
Besides further broadening the Alzheimer’s therapeutic pipeline, researchers urge a return to Phase 2, using artificial intelligence tools to streamline aspects of trials.
48 RESULTS
Sort By:
Besides further broadening the Alzheimer’s therapeutic pipeline, researchers urge a return to Phase 2, using artificial intelligence tools to streamline aspects of trials.
In early Alzheimer’s disease, the pattern of tau deposition also strongly predicts areas destined for subsequent degeneration.
Positive allosteric modulators improve learning and memory in mouse models of AD and epilepsy.